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For our 20-year anniversary, we have chosen to celebrate
by commissioning seven editorials that look back at
seven original articles that we have published over the
last two decades. These articles are among the most
highly cited, downloaded, and referenced original articles
that the journal has published. We were delighted that
all the original lead authors agreed to take up our chal-
lenge to look back, with hindsight at the way in which
their articles have become so impactful. We wanted to
let our authors be our advocates, and indeed, they have
done so, in a humble yet striking way.
For example, in March 2005, Arthritis Research and
Therapy published “Systemic lupus erythematosus in-
duced by anti-tumour necrosis factor alpha therapy: a
French national survey” [1]. As the lead author Michel
De Bandt confesses, he thought “The subject seemed
quite banal at the time,” but in fact, it was the first set of
observations that anti-TNF drugs can cause drug-
induced lupus. ANA and anti-DNA are now routinely,
before patients start starting an anti-TNF mainly on the
basis of this publication.
Over 12 years ago, we published a paper on the use of
the interleukin-1 (IL1) inhibitor anakinra in acute gout
[2]. It was a pilot study comprising an extended case
series and animal data to validate the concept that IL1
played a pivotal role in the initiation of MSU crystal-
induced inflammation. As Alexander So recollects, he
chose to publish in Arthritis Research and Therapy be-
cause it publishes proof-of-concept studies rapidly, in
comparison with conventional journals. The finding that
anakinra, was effective to treat gout proof that the
inflammasome (intracellular “machine” that processes
pro-IL1 to mature and secreted IL1) is responsible for
pathogenesis in gout. Anakinra is now used to treat pa-
tients who are unable to receive or have contraindica-
tions to conventional drugs used to treat acute gout.
A study led by Karim Raza published in 2005 [3] identi-
fied that people with rheumatoid arthritis (RA) assessed,
within 3 months of symptoms onset, had a synovial fluid
cytokine profile that was distinct from that of patients
with other inflammatory arthritides of similarly short dur-
ation. This profile, which was transient, was characterized
by cytokines of stromal and T cell origin. These findings
suggested that the first few months after symptom onset
were associated with changes in the early RA joint that
differed from those operating at later stages. The implica-
tions from these findings was later disease is not more of
early disease have provided the rationale for some of the
ongoing early prevention studies in RA.
In 2008, we published “Cardiovascular (CV) in patients
with rheumatoid arthritis: results from the QUEST-RA
Study” [4]. As Antonio Naranjo and Iván Ferraz-Amaro
reflect, the QUEST-RA study has opened new research
avenues in a field that has become essential to the care
of patients with RA.
The QUEST-RA study’s finding that treatments for
RA reduced cardiovascular risk in patients with RA was
fundamental to understanding the relationship between
systemic inflammation and CV disease. This has proven
to be a crucial result, not only for patients with inflam-
matory arthritis, but also for the field of CV disease in
healthy populations.
When anti-TNF was first licensed for RA, physicians
were cautious regarding the new biologics and possible
cancer development. Thus, a key unanswered question
remained. What was the background rate of malignan-
cies in patients with RA? Was the occurrence of malig-
nancies in patients with RA different from the GP? In
2008, we published the answer [5]. As Teresa A. Simon
describes, “our extensive literature meta-analysis review
showed no difference in overall malignancy rates be-
tween the RA population and the GP.”
A decade has passed since Désirée van der Heijde and
Robert Landewé published their comparison of the effect
of adalimumab with data from a historic cohort on the
progression of structural damage in the spine of patients
with ankylosing spondylitis (AS) [6]. The somewhat un-
usual comparator group was formed by a historic cohort
of patients with AS treated with non-steroidal anti-
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inflammatory drugs (NSAIDs) and conventional synthetic
disease-modifying anti-rheumatic drugs (csDMARDs). No
effect could be observed, and there is still no definite proof
that TNF inhibitors (TNFi) inhibit spinal structural
damage. This uncoupling of inflammation from damage
has proven with time to be a very important biological
finding.
We the final word to Annette van der Helm-van Mil
whose study in 2005, “Antibodies to citrullinated pro-
teins and differences in clinical progression of rheuma-
toid arthritis,” was one of the first to link citrullination
with disease progression in RA [7]. She wisely reflects,
“In general, studies that change the field are those that
either improve the understanding of disease pathogen-
esis or have an impact on patients care in daily practice.
Such important studies are relatively easy recognized in
retrospect, but are less easy recognizable at the time of
first reporting, because subsequent studies are generally
required to validate or expand on the initial findings.”
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